{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T07:44:11Z","timestamp":1785397451741,"version":"3.56.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.clml.2024.05.013","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T15:42:36Z","timestamp":1716219756000},"page":"e320-e328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Unmet Needs in the First-Line Treatment of Diffuse Large B-cell Lymphoma: Expert Recommendations From the Asia-Pacific Region With a Focus on the Challenging Subtypes"],"prefix":"10.1016","volume":"24","author":[{"given":"Daryl","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason Yongsheng","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kitsada","family":"Wudhikarn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond Siu Ming","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limei","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lalita","family":"Norasetthada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Chung","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.05.013_bib0001","unstructured":"Ferlay J, Ervik M, Lam F, et al. (2024). Global Cancer Observatory: Cancer Today (version 1.1). Lyon, France: International Agency for Research on Cancer. Available from: https:\/\/gco.iarc.who.int\/today. Accessed February 2024."},{"key":"10.1016\/j.clml.2024.05.013_sbref0002","series-title":"StatPearls Treasure Island (FL)","article-title":"Diffuse large B-cell lymphoma","author":"Padala","year":"2023"},{"issue":"5","key":"10.1016\/j.clml.2024.05.013_bib0003","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.3109\/10428194.2012.729056","article-title":"Frequency and distribution of lymphoma types in a tertiary care hospital in South India: analysis of 5115 cases using the World Health Organization 2008 classification and comparison with world literature","volume":"54","author":"Arora","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2024.05.013_bib0004","series-title":"Maria de Lourdes Ribeiro de Souza da C, ed. Epidemiology Insights","first-page":"16","article-title":"Epidemiology of lymphoid malignancy in Asia","author":"Zahra","year":"2012"},{"issue":"4","key":"10.1016\/j.clml.2024.05.013_bib0005","first-page":"1262","article-title":"Increasing incidence of B-Cell non-Hodgkin lymphoma and occurrence of second primary malignancies in South Korea: 10-year follow-up using the Korean National Health Information Database","volume":"52","author":"Kim","year":"2020","journal-title":"Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.clml.2024.05.013_bib0006","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/hon.2392","article-title":"Non-hodgkin lymphoma in South East Asia: an analysis of the histopathology, clinical features, and survival from Thailand","volume":"36","author":"Intragumtornchai","year":"2018","journal-title":"Hematol Oncol"},{"issue":"8","key":"10.1016\/j.clml.2024.05.013_bib0007","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jfma.2016.11.006","article-title":"Lymphoma in Taiwan: Review of 1347 neoplasms from a single institution according to the 2016 revision of the World Health Organization classification","volume":"116","author":"Chuang","year":"2017","journal-title":"J Formos Med Assoc"},{"issue":"5","key":"10.1016\/j.clml.2024.05.013_bib0008","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1053\/j.seminhematol.2023.11.004","article-title":"Epidemiology and etiology of diffuse large B-cell lymphoma","volume":"60","author":"Wang","year":"2023","journal-title":"Semin Hematol"},{"issue":"Suppl 5","key":"10.1016\/j.clml.2024.05.013_bib0009","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2024.05.013_bib0010","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) B-cell lymphomas, Version 5.2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/b-cell.pdf. Accessed July 2023."},{"issue":"1","key":"10.1016\/j.clml.2024.05.013_bib0011","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.14136","article-title":"Guidelines for the management of diffuse large B-cell lymphoma","volume":"174","author":"Chaganti","year":"2016","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.clml.2024.05.013_bib0012","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.05.013_bib0013","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.clml.2024.05.013_bib0014","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","article-title":"Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma","volume":"24","author":"Habermann","year":"2006","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2024.05.013_bib0015","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","article-title":"CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group","volume":"12","author":"Pfreundschuh","year":"2011","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.05.013_bib0016","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.05.013_bib0017","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2024.05.013_bib0018","first-page":"51","article-title":"Current frontline treatment of diffuse large b-cell lymphoma","volume":"36","author":"Spinner","year":"2022","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"10.1016\/j.clml.2024.05.013_bib0019","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3109\/10428194.2012.698739","article-title":"Inferior progression-free survival for Thai patients with diffuse large B-cell lymphoma treated under Universal Coverage Scheme: the impact of rituximab inaccessability","volume":"54","author":"Intragumtornchai","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.clml.2024.05.013_bib0020","doi-asserted-by":"crossref","first-page":"17950","DOI":"10.1038\/s41598-021-97455-5","article-title":"Socioeconomic inequalities in treatment and relative survival among patients with diffuse large B-cell lymphoma: a Hong Kong population-based study","volume":"11","author":"Lee","year":"2021","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.clml.2024.05.013_bib0021","doi-asserted-by":"crossref","first-page":"e548","DOI":"10.1016\/S1470-2045(13)70450-9","article-title":"Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines","volume":"14","author":"Tan","year":"2013","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clml.2024.05.013_bib0022","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s12672-023-00754-8","article-title":"Evolving therapeutic landscape of diffuse large B-cell lymphoma: challenges and aspirations","volume":"14","author":"Chan","year":"2023","journal-title":"Discov Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.05.013_bib0023","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.7314\/APJCP.2014.15.4.1703","article-title":"Impact of inadequate doses of rituximab in the treatment of diffuse large B cell lymphoma in Malaysian patients","volume":"15","author":"Gan","year":"2014","journal-title":"Asian Pac J Cancer Prev"},{"issue":"4","key":"10.1016\/j.clml.2024.05.013_bib0024","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4103\/0971-5851.125250","article-title":"Histopathological pattern of lymphomas and clinical presentation and outcomes of diffuse large B cell lymphoma: a multicenter registry based study from India","volume":"34","author":"Nimmagadda","year":"2013","journal-title":"Indian J Med Paediatr Oncol"},{"key":"10.1016\/j.clml.2024.05.013_bib0025","article-title":"Diffuse large B-cell lymphoma: clinical presentation and treatment outcomes from the oncocollect lymphoma registry","volume":"11","author":"Nair","year":"2021","journal-title":"Front Oncol"},{"issue":"14","key":"10.1016\/j.clml.2024.05.013_bib0026","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A Predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clml.2024.05.013_bib0027","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","article-title":"Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era","volume":"28","author":"Ziepert","year":"2010","journal-title":"J Clin Oncol"},{"issue":"16","key":"10.1016\/j.clml.2024.05.013_bib0028","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.05.013_bib0029","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/bjh.18197","article-title":"Outcomes of relapsed\/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-a population-based study of 736 patients","volume":"198","author":"Harrysson","year":"2022","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2024.05.013_bib0030","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cac2.12126","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from a multicenter real-world study in China","volume":"41","author":"Wang","year":"2021","journal-title":"Cancer Commun (Lond)"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.05.013_bib0031","doi-asserted-by":"crossref","first-page":"12106","DOI":"10.1182\/blood-2022-169045","article-title":"Diffuse large B-cell lymphoma (DLBCL): a structured literature review of the epidemiology, treatment guidelines, and real-world treatment patterns","volume":"140","author":"Garg","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.05.013_bib0032","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1600-0609.2010.01540.x","article-title":"Gem-(R)CHOP versus (R)CHOP: a randomized phase II study of gemcitabine combined with (R)CHOP in untreated aggressive non-Hodgkin's lymphoma\u2013EORTC lymphoma group protocol 20021 (EudraCT number 2004-004635-54)","volume":"86","author":"Aurer","year":"2011","journal-title":"Eur J Haematol"},{"issue":"21","key":"10.1016\/j.clml.2024.05.013_bib0033","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2024.05.013_bib0034","unstructured":"POLIVY (polatuzumab vedotin-piiq) [prescribing information]. South San Francisco, California; Genentech, Inc; 2019. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761121s000lbl.pdf. Accessed September 2023. 2019. Accessed September 2023."},{"key":"10.1016\/j.clml.2024.05.013_bib0035","doi-asserted-by":"crossref","unstructured":"Herrera AF, McCord R, Kimes P, et al. Risk profiling of patients with previously untreated diffuse large B cell lymphoma (DLBCL) by measuring circulating tumor DNA (ctDNA): Results from the POLARIX study. Presented at ASH 2022. Oral presentation 542.","DOI":"10.1182\/blood-2022-157559"},{"issue":"16","key":"10.1016\/j.clml.2024.05.013_bib0036","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood.2022017734","article-title":"Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial","volume":"141","author":"Song","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.05.013_bib0037","series-title":"FDA approves polatuzumab vedotin-piiq for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma","year":"2023"},{"key":"10.1016\/j.clml.2024.05.013_bib0038","unstructured":"Polatuzumab vedotin in combination for untreated diffuse large B-cell lymphoma. https:\/\/www.nice.org.uk\/guidance\/ta874. 2023. Accessed 29 September 2023."},{"issue":"5","key":"10.1016\/j.clml.2024.05.013_bib0039","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00277-023-05161-1","article-title":"Superiority of polatuzumab vedotin over other novel agents in previously untreated ABC-type diffuse large B-cell lymphoma: A network meta-analysis of 20 RCTs","volume":"102","author":"Sheng","year":"2023","journal-title":"Ann Hematol"},{"issue":"8","key":"10.1016\/j.clml.2024.05.013_bib0040","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJMc2306105","article-title":"Cell-of-origin subtypes and therapeutic benefit from polatuzumab vedotin","volume":"389","author":"Palmer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2024.05.013_bib0041","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2023022048","article-title":"Cell-of-origin effect of polatuzumab vedotin in diffuse large B-cell lymphoma: No ordinary subgroup analysis","author":"Russler-Germain","year":"2023","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2024.05.013_bib0042","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/bjh.18869","article-title":"Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany","volume":"202","author":"Kambhampati","year":"2023","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2024.05.013_bib0043","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2024.05.013_bib0044","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00520-023-07763-x","article-title":"Patients' experience with chimeric antigen receptor T-cell therapy for DLBCL in China: a qualitative study","volume":"31","author":"Mao","year":"2023","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2024.05.013_bib0045","doi-asserted-by":"crossref","DOI":"10.1002\/hon.3057","article-title":"A unique hub-and-spoke model to optimize patient management in lymphoma using novel chimeric antigen receptor-T cell therapy in Southeast and South Asia","author":"Lim","year":"2022","journal-title":"Hematol Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.05.013_bib0046","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.3324\/haematol.2021.279189","article-title":"One and a half million hematopoietic stem cell transplants: continuous and differential improvement in worldwide access with the use of non-identical family donors","volume":"107","author":"Niederwieser","year":"2022","journal-title":"Haematologica"},{"issue":"11","key":"10.1016\/j.clml.2024.05.013_bib0047","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.21.00202","article-title":"Improving survival and predicting toxicity in older patients with DLBCL: a delicate balance","volume":"39","author":"Smith","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"10.1016\/j.clml.2024.05.013_bib0048","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1634\/theoncologist.2014-0093","article-title":"Exclusion of older patients from ongoing clinical trials for hematological malignancies: AN evaluation of the National Institutes of Health Clinical Trial Registry","volume":"19","author":"Hamaker","year":"2014","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.clml.2024.05.013_bib0049","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/onco.13610","article-title":"Challenges and opportunities in the management of diffuse large B-cell lymphoma in older patients","volume":"26","author":"Di","year":"2021","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.clml.2024.05.013_bib0050","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jgo.2012.12.001","article-title":"Factors affecting survival in patients aged 60 and over with diffuse large B cell lymphoma failing first-line therapy","volume":"4","author":"Lowry","year":"2013","journal-title":"J Geriatr Oncol"},{"issue":"7","key":"10.1016\/j.clml.2024.05.013_bib0051","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.ejca.2005.01.010","article-title":"Independent prognostic effect of co-morbidity in lymphoma patients: results of the population-based Eindhoven Cancer Registry","volume":"41","author":"van Spronsen","year":"2005","journal-title":"Eur J Cancer"},{"issue":"22","key":"10.1016\/j.clml.2024.05.013_bib0052","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","article-title":"Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology","volume":"36","author":"Mohile","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2024.05.013_bib0053","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1200\/JCO.20.02465","article-title":"Simplified geriatric assessment in older patients with diffuse large B-cell lymphoma: the prospective elderly project of the Fondazione Italiana Linfomi","volume":"39","author":"Merli","year":"2021","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.clml.2024.05.013_bib0054","doi-asserted-by":"crossref","first-page":"5094","DOI":"10.1182\/blood.V126.23.5094.5094","article-title":"80% dose R-CHOP is suitable chemotherapy for very elderly patients with DLBCL","volume":"126","author":"Takahashi","year":"2015","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.clml.2024.05.013_bib0055","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1182\/blood.V116.21.853.853","article-title":"Rituximab and reduced dose CHOP (R-mini-CHOP) for patients over 80 years with diffuse large B-cell lymphoma (DLBCL) \u2013 Groupe d'etude des lymphomes De l'adulte (GELA) Study LNH03-7B","volume":"116","author":"Peyrade","year":"2010","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.clml.2024.05.013_bib0056","doi-asserted-by":"crossref","first-page":"8536","DOI":"10.1200\/jco.2013.31.15_suppl.8536","article-title":"Long-term follow-up of the GELA LNH 03-7B study: a prospective phase II study of 150 patients over 80 years with diffuse large B-cell lymphoma (DLBCL) treated with RminiCHOP","volume":"31","author":"Peyrade","year":"2013","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.clml.2024.05.013_bib0057","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/ajh.27151","article-title":"R-miniCHOP versus R-CHOP in elderly patients with diffuse large B-cell lymphoma: a propensity matched population-based study","volume":"99","author":"Al-Sarayfi","year":"2024","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2024.05.013_bib0058","doi-asserted-by":"crossref","unstructured":"Jerkeman M, Lepp\u00e4 S, Hamfjord J, Brown P, Ekberg S, Jos\u00e9 Mar\u00eda Ferreri A. S227: Initial safety data from the phase 3 polar bear trial in elderly or frail patients with diffuse large cell lymphoma, comparing R-Pola-Mini-Chp and R-Mini-Chop. Hemasphere.7:e91359ec. 10.1097\/01.HS9.0000967820.91359.ec","DOI":"10.1097\/01.HS9.0000967820.91359.ec"},{"issue":"19","key":"10.1016\/j.clml.2024.05.013_bib0059","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1200\/JCO.2007.14.1242","article-title":"Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma","volume":"26","author":"Hershman","year":"2008","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.clml.2024.05.013_bib0060","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.clml.2024.05.013_bib0061","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jgo.2015.01.003","article-title":"Comparative effectiveness of anthracycline-containing chemotherapy in United States veterans age 80 and older with diffuse large B-cell lymphoma","volume":"6","author":"Carson","year":"2015","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.clml.2024.05.013_bib0062","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s12979-020-00188-8","article-title":"Frontline treatments in extremely elderly patients with diffuse large B-cell lymphoma: A population-based study in Taiwan, 2010-2015","volume":"17","author":"Huang","year":"2020","journal-title":"Immun Ageing"},{"issue":"10","key":"10.1016\/j.clml.2024.05.013_bib0063","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00277-016-2768-x","article-title":"R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma","volume":"95","author":"Laribi","year":"2016","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.clml.2024.05.013_bib0064","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/cncr.29290","article-title":"Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma","volume":"121","author":"Williams","year":"2015","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.clml.2024.05.013_bib0065","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2013.49.7586","article-title":"De novo treatment of diffuse large B-cell lymphoma with rituximab, cyclophosphamide, vincristine, gemcitabine, and prednisolone in patients with cardiac comorbidity: a United Kingdom National Cancer Research Institute trial","volume":"32","author":"Fields","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2024.05.013_bib0066","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1182\/bloodadvances.2020002982","article-title":"Long-term outcomes of R-CEOP show curative potential in patients with DLBCL and a contraindication to anthracyclines","volume":"5","author":"Moccia","year":"2021","journal-title":"Blood Adv"},{"issue":"8","key":"10.1016\/j.clml.2024.05.013_bib0067","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3324\/haematol.2017.186569","article-title":"Rituximab plus bendamustine as front-line treatment in frail elderly (> 70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi","volume":"103","author":"Storti","year":"2018","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.clml.2024.05.013_bib0068","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.clml.2024.05.013_bib0069","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.clml.2024.05.013_bib0070","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clml.2024.05.013_bib0071","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/17474086.2019.1677152","article-title":"Clinical impact of the cell-of-origin classification based on immunohistochemistry criteria and Lymph2Cx of diffuse large B-Cell lymphoma patients in a South-East Asian population: a single center experience and review of the literature","volume":"12","author":"Lee","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"28","key":"10.1016\/j.clml.2024.05.013_bib0072","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Green","year":"2012","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.clml.2024.05.013_bib0073","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1200\/JCO.19.00743","article-title":"Prognostic significance of MYC rearrangement and translocation partner in diffuse large B-cell lymphoma: a study by the lunenburg lymphoma biomarker consortium","volume":"37","author":"Rosenwald","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2024.05.013_bib0074","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw257","article-title":"Beyond RCHOP: a blueprint for diffuse large B cell lymphoma research","volume":"108","author":"Nowakowski","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.clml.2024.05.013_bib0075","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25460","article-title":"Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Liu","year":"2019","journal-title":"Am J Hematol"},{"issue":"15","key":"10.1016\/j.clml.2024.05.013_bib0076","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1182\/blood-2014-05-578963","article-title":"Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis","volume":"124","author":"Petrich","year":"2014","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.clml.2024.05.013_bib0077","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1200\/JCO.2017.72.2157","article-title":"Outcomes of patients with double-hit lymphoma who achieve first complete remission","volume":"35","author":"Landsburg","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2024.05.013_bib0078","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/S2352-3026(18)30177-7","article-title":"Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study","volume":"5","author":"Dunleavy","year":"2018","journal-title":"Lancet Haematol"},{"issue":"6","key":"10.1016\/j.clml.2024.05.013_bib0079","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/bjh.12982","article-title":"Double hit lymphoma: the MD Anderson Cancer Center clinical experience","volume":"166","author":"Oki","year":"2014","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2024.05.013_bib0080","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/bjh.13463","article-title":"Front-line, dose-escalated immunochemotherapy is associated with a significant progression-free survival advantage in patients with double-hit lymphomas: a systematic review and meta-analysis","volume":"170","author":"Howlett","year":"2015","journal-title":"Br J Haematol"},{"issue":"16_suppl","key":"10.1016\/j.clml.2024.05.013_bib0081","doi-asserted-by":"crossref","first-page":"7517","DOI":"10.1200\/JCO.2022.40.16_suppl.7517","article-title":"Outcomes by BCL2 and MYC expression and rearrangements in untreated diffuse large B-cell lymphoma (DLBCL) from the POLARIX trial","volume":"40","author":"Morschhauser","year":"2022","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2024.05.013_bib0082","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JOP.2015.009647","article-title":"A Clinician's approach to double-hit lymphoma: Identification, evaluation, and management","volume":"12","author":"Staton","year":"2016","journal-title":"J Oncol Pract"},{"issue":"20","key":"10.1016\/j.clml.2024.05.013_bib0083","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Hu","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.clml.2024.05.013_bib0084","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.12763","article-title":"MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"165","author":"Perry","year":"2014","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2024.05.013_bib0085","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1182\/asheducation-2017.1.295","article-title":"Current treatment of double hit and double expressor lymphoma","volume":"2017","author":"Reagan","year":"2017","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"1","key":"10.1016\/j.clml.2024.05.013_bib0086","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00432-018-2771-9","article-title":"DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma","volume":"145","author":"Zhang","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.05.013_bib0087","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hon.2902","article-title":"Impact of initial chemotherapy regimen on outcomes for patients with double-expressor lymphoma: a multi-center analysis","volume":"39","author":"D'Angelo","year":"2021","journal-title":"Hematol Oncol"},{"issue":"4","key":"10.1016\/j.clml.2024.05.013_bib0088","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41375-018-0320-9","article-title":"Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma","volume":"33","author":"Dodero","year":"2019","journal-title":"Leukemia"},{"issue":"38","key":"10.1016\/j.clml.2024.05.013_bib0089","doi-asserted-by":"crossref","first-page":"e30620","DOI":"10.1097\/MD.0000000000030620","article-title":"DA-EPOCH-R improves the prognosis of patients with double-expressor lymphoma: A single-center retrospective study and meta-analysis","volume":"101","author":"Zhan","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"2","key":"10.1016\/j.clml.2024.05.013_bib0090","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3324\/haematol.2021.278613","article-title":"Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy","volume":"109","author":"Roschewski","year":"2024","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.clml.2024.05.013_bib0091","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1182\/bloodadvances.2021005602","article-title":"Autologous stem cell transplantation for large B-cell lymphoma with secondary central nervous system involvement","volume":"6","author":"Akin","year":"2022","journal-title":"Blood Adv"},{"issue":"14","key":"10.1016\/j.clml.2024.05.013_bib0092","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1182\/blood-2013-06-453084","article-title":"How I treat CNS lymphomas","volume":"122","author":"Rubenstein","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.05.013_bib0093","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3324\/haematol.2016.149120","article-title":"Guidelines for diagnosis, prevention and management of central nervous system involvement in diffuse large B-cell lymphoma patients by the Spanish Lymphoma Group (GELTAMO)","volume":"102","author":"Penalver","year":"2017","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.clml.2024.05.013_bib0094","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1002\/ajh.25558","article-title":"Characteristics, management and outcome of DLBCL patients, presenting with simultaneous systemic and CNS disease at diagnosis: a retrospective multicenter study","volume":"94","author":"Perry","year":"2019","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.clml.2024.05.013_bib0095","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/bjh.16064","article-title":"Outcomes of synchronous systemic and central nervous system (CNS) involvement of diffuse large B-cell lymphoma are dictated by the CNS disease: a collaborative study of the Australasian Lymphoma Alliance","volume":"187","author":"Wight","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.clml.2024.05.013_bib0096","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1016\/S2352-3026(20)30366-5","article-title":"MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial","volume":"8","author":"Ferreri","year":"2021","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.clml.2024.05.013_bib0097","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1002\/jha2.296","article-title":"Excellent survival after R-Hyper-CVAD in hospitalized patients with high-risk large B-cell lymphoma: The Karolinska experience","volume":"2","author":"Sonnevi","year":"2021","journal-title":"EJHaem"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024001848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,24]],"date-time":"2024-08-24T04:28:30Z","timestamp":1724473710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024001848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":97,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2152265024001848"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.05.013","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unmet Needs in the First-Line Treatment of Diffuse Large B-cell Lymphoma: Expert Recommendations From the Asia-Pacific Region With a Focus on the Challenging Subtypes","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.05.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}